TG 02

Drug Profile

TG 02

Alternative Names: SB 1317; TG02

Latest Information Update: 25 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator S*BIO
  • Developer National Cancer Institute (USA); S*BIO; Tragara Pharmaceuticals
  • Class Antineoplastics; Heterocyclic compounds with 4 or more rings; Small molecules
  • Mechanism of Action Cyclin-dependent kinase inhibitors; Extracellular signal-regulated MAP kinase inhibitors; Fms-like tyrosine kinase 3 inhibitors; Janus kinase-2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Anaplastic astrocytoma; Glioblastoma
  • Phase I Chronic lymphocytic leukaemia; Leukaemia; Multiple myeloma
  • Preclinical Solid tumours
  • No development reported Cancer

Most Recent Events

  • 25 Jul 2017 European Organisation for Research and Treatment of Cancer and Tragara Pharmaceuticals plan the STEAM phase I trial for Anaplastic astrocytoma and Glioblastoma (Newly diagnosed, Second-line therapy or greater) in Switzerland (NCT03224104)
  • 01 Apr 2017 Pharmacodynamics data from a preclinical study in Solid tumours presented at the 108th Annual Meeting of the American Association for Cancer Research (AACR-2017)
  • 27 Oct 2016 The National Cancer Institute plans a phase I/II trial for Glioblastoma and Anaplastic astrocytoma (Recurrent, Late-stage disease, Combination therapy, Second-line therapy or greater) in USA (PO) (NCT02942264)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top